TuHURA Biosciences (STU:PL3) Stock Based Compensation: €6.70 Mil (TTM As of Mar. 2026)


STU:PL3 TuHURA Biosciences Inc STU:PL3
14 GF Score
Price €1.96
! 1 Warning Sign
View Full Analysis

What is TuHURA Biosciences Stock Based Compensation?

TuHURA Biosciences STU:PL3 +0.51% 14 Stock Based Compensation is €6.70 Mil as of Mar. 2026. GuruFocus rates STU:PL3 with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

TuHURA Biosciences's Stock Based Compensation for the three months ended in Mar. 2026 was €2.42 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €6.70 Mil.

TuHURA Biosciences Stock Based Compensation Related Terms

TuHURA Biosciences Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for TuHURA Biosciences's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TuHURA Biosciences Stock Based Compensation Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
0.58 0.21 0.44 1.87 5.49

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 1.22 1.39 1.68 2.42
STU:PL3
14GF Score
TuHURA Biosciences Inc STU:PL3
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TuHURA Biosciences Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.70 Mil.

What does a Stock Based Compensation of €6.70 Mil mean?
TuHURA Biosciences (STU:PL3) has a Stock Based Compensation of €6.70 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for TuHURA Biosciences and its competitors.
Is TuHURA Biosciences' Stock Based Compensation too high?
TuHURA Biosciences' current Stock Based Compensation is €6.70 Mil. Overall, TuHURA Biosciences has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does TuHURA Biosciences' Stock Based Compensation compare to ACOG and MENS?
TuHURA Biosciences' Stock Based Compensation of €6.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for TuHURA Biosciences and its competitors. TuHURA Biosciences's current Stock Based Compensation is €6.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TuHURA Biosciences stock overvalued right now?
TuHURA Biosciences (STU:PL3) has a current Stock Based Compensation of €6.70 Mil. The current Stock Based Compensation is €6.70 Mil. TuHURA Biosciences' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For TuHURA Biosciences (STU:PL3), the current Stock Based Compensation is €6.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TuHURA Biosciences Business Description

Other Exchanges HURA:USA
Address 10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
14GF Score

Get the complete analysis for STU:PL3

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.96
Price